Loading...
XSHG
600285
Market cap1.79bUSD
Jul 10, Last price  
22.96CNY
1D
-0.95%
1Q
1.46%
Jan 2017
79.94%
IPO
273.94%
Name

Henan Lingrui Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600285 chart
P/E
22.62
P/S
3.88
EPS
1.01
Div Yield, %
3.48%
Shrs. gr., 5y
-0.83%
Rev. gr., 5y
10.03%
Revenues
3.31b
+10.31%
340,046,509399,374,464392,177,875520,330,937423,244,212463,281,143381,238,790448,778,162562,700,777686,974,842826,274,1171,070,767,1931,439,313,4721,848,525,0852,053,113,1802,157,052,0012,331,577,4462,693,510,9183,001,862,2133,311,472,606
Net income
568m
+22.09%
15,336,46218,465,89411,119,99569,496,69310,476,57429,314,87748,557,68129,851,40542,453,610105,367,05876,170,879132,477,475345,772,174217,112,186243,263,838294,436,954325,489,250361,542,665465,304,594568,109,302
CFO
813m
-2.57%
35,511,22633,428,27026,763,98715,985,21643,720,671132,607,233040,487,86015,434,351127,269,669124,320,875156,818,48163,262,545105,972,634436,248,604450,154,297450,529,975845,686,168834,909,734813,428,748
Dividend
Jun 20, 20240.8 CNY/sh

Profile

Henan Lingrui Pharmaceutical Co., Ltd. produces and sells medicines in China. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, tinctures, etc. covering approximately 100 product varieties. Its products include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, Shenqi Hypoglycemic capsules, and others. Henan Lingrui Pharmaceutical Co., Ltd. was founded in 1992 and is based in Xinyang, China.
URL
http://www.lingrui.com/
IPO date
Oct 18, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,311,473
10.31%
3,001,862
11.45%
Cost of revenue
2,363,744
2,441,672
Unusual Expense (Income)
NOPBT
947,729
560,190
NOPBT Margin
28.62%
18.66%
Operating Taxes
84,928
51,703
Tax Rate
8.96%
9.23%
NOPAT
862,800
508,487
Net income
568,109
22.09%
465,305
28.70%
Dividends
(344,285)
(282,126)
Dividend yield
3.55%
3.81%
Proceeds from repurchase of equity
(787)
BB yield
0.01%
Debt
Debt current
141,221
95,030
Long-term debt
13,924
12,394
Deferred revenue
39,784
38,553
Other long-term liabilities
1
1
Net debt
(1,681,039)
(1,420,390)
Cash flow
Cash from operating activities
813,429
834,910
CAPEX
(21,198)
Cash from investing activities
(243,007)
Cash from financing activities
(272,734)
FCF
921,755
534,647
Balance
Cash
1,499,101
1,329,717
Long term investments
337,083
198,097
Excess cash
1,670,610
1,377,720
Stockholders' equity
2,185,042
2,363,285
Invested Capital
1,316,054
1,224,955
ROIC
67.91%
39.37%
ROCE
31.45%
21.28%
EV
Common stock shares outstanding
566,410
568,170
Price
17.11
31.21%
13.04
-17.47%
Market cap
9,691,276
30.81%
7,408,930
-17.25%
EV
8,017,894
5,996,087
EBITDA
1,025,353
636,440
EV/EBITDA
7.82
9.42
Interest
589
775
Interest/NOPBT
0.06%
0.14%